3-deazaguanine, a candidate drug for the chemotherapy of breast carcinomas?

3-Deazaguanine (3-DG) is a new purine antagonist that is active against slow- and rapid-growing solid experimental tumors, especially those that are models for human breast carcinomas. These tumors include mammary adenocarcinomas 13762, R3230AC, and C3H/16C. 3-DG also showed positive activity against leukemias L1210 and L1210/araC, adenocarcinoma 755, and EMT-6 mammary adenocarcinoma. On the basis of its activity against these tumors, 3-DG is to undergo clinical trials.